PRINCETON, N.J., Oct. 27, 2016 /PRNewswire/ -- Braeburn Pharmaceuticals, Inc. has been awarded a "Best of What's New" award for its Probuphine (buprenorphine) implant, the first and only implant for the maintenance treatment of opioid addiction in clinically stable patients. Each year Popular Science chooses 12 of the most transformative advances in health and has selected Probuphine as one of this year's winners.
Probuphine was developed to offer a new way to treat opioid addiction, a disease that has reached epidemic proportions and according to the CDC in 2014 claimed the lives of 78 people in the U.S. each day. Probuphine contains buprenorphine, a drug that reduces the symptoms of withdrawal and cravings for opioids. Buprenorphine-containing products have been successfully used to treat opioid dependence since 2002. As a six-month subdermal implant, Probuphine received fast track designation by the FDA for its potential to reduce the risks of diversion, abuse and accidental pediatric exposure.
"We are honored that Probuphine was recognized by Popular Science as an innovative way to treat opioid use disorder," said Behshad Sheldon, President and Chief Executive Officer, Braeburn Pharmaceuticals. "Patients with opioid addiction deserve to have as many novel approaches available to them as those with other chronic diseases. Probuphine provides up to six months of treatment after a single in-office procedure."
"The Best of What's New awards honor the innovations that shape the future" says Kevin Gray, Executive Editor, Popular Science. "From life-saving technology to incredible space engineering to gadgets that are just breathtakingly cool, this is the best of what's new."
About Best of What's New
Each year, the editors of Popular Science review thousands of products in search of the top 100 tech innovations of the year—breakthrough products and technologies that represent a significant leap in their categories. The winners, the Best of What's New, are awarded inclusion in the much-anticipated November/December issue of Popular Science, which has been the most widely read issue of the year since the debut of Best of What's New in 1988. Best of What's New awards are presented to 100 new products and technologies in 11 categories: Automotive, Aviation, Computing, Engineering, Gadgets, Entertainment, Security, Software, Home, Health and Recreation.
About Popular Science
Founded in 1872, Popular Science is the world's largest science and technology magazine, with a circulation of 1.3 million and 6.8 million bi-monthly readers. In each issue, Popular Science reports on the intersection of science and everyday life, with an eye toward what's new and why it matters. Popular Science is published by Bonnier Active Media, a subsidiary of Bonnier Corporation.
About Braeburn Pharmaceuticals
Braeburn Pharmaceuticals, an Apple Tree Partners company, is a commercial stage pharmaceutical company delivering individualized medicine in neuroscience. Long-acting therapeutic treatment options can be essential to improving patient outcomes and facilitating recovery in neurological and psychiatric disorders, which are often complicated by stigma and present significant public health challenges. Probuphine, Braeburn's long-acting buprenorphine implant, was approved by the FDA in May 2016. Braeburn's investigational product pipeline consists of long-acting implantable and injectable therapies for serious neurological and psychiatric disorders, including opioid addiction, pain, and schizophrenia. Braeburn's pipeline products are at various stages of clinical development and include CAM2038, weekly and monthly subcutaneous injection depot formulations of buprenorphine, being investigated in opioid addiction and pain and a risperidone six-month implant being investigated in schizophrenia. More information on Braeburn can be found at www.braeburnpharmaceuticals.com.
PROBUPHINE is indicated for the maintenance treatment of opioid dependence in patients who have achieved and sustained prolonged clinical stability on low-to-moderate doses of a transmucosal buprenorphine containing product (i.e., doses of no more than 8 mg per day of Subutex or Suboxone sublingual tablet or generic equivalent). PROBUPHINE should be used as part of a complete treatment program that includes counseling and psychosocial support.
Probuphine is the only six-month treatment for opioid dependence that delivers buprenorphine continuously using Titan Pharmaceuticals' (NASDAQ: TTNP) ProNeura™ technology. Probuphine is placed under the skin of the upper arm during an outpatient office procedure and is removed in a similar manner. For more information, visit www.probuphine.com.
Important Safety Information
PROBUPHINE is indicated for the maintenance treatment of opioid dependence in patients who have achieved and sustained prolonged clinical stability on low-to-moderate doses of a transmucosal buprenorphine-containing product (i.e., doses of no more than 8 mg per day of Subutex or Suboxone sublingual tablet or generic equivalent).
PROBUPHINE should be used as part of a complete treatment program to include counseling and psychosocial support.
PROBUPHINE is not appropriate for new entrants to treatment and patients who have not achieved and sustained prolonged clinical stability, while being maintained on buprenorphine 8 mg per day or less of a Subutex or Suboxone sublingual tablet or generic equivalent.
WARNING: IMPLANT MIGRATION, PROTRUSION, EXPULSION and NERVE DAMAGE ASSOCIATED WITH INSERTION and REMOVAL
Risk Associated with Insertion and Removal
Insertion and removal of PROBUPHINE are associated with the risk of implant migration, protrusion, expulsion resulting from the procedure. Rare but serious complications including nerve damage and migration resulting in embolism and death may result from improper insertion of drug implants inserted in the upper arm. Additional complications may include local migration, protrusion and expulsion. Incomplete insertions or infections may lead to protrusion or expulsion.
Because of the risks associated with insertion and removal, PROBUPHINE is available only through a restricted program called the PROBUPHINE REMS Program. All Healthcare Providers must successfully complete a live training program on the insertion and removal procedures and become certified, prior to performing insertions or prescribing PROBUPHINE implants. Patients must be monitored to ensure that PROBUPHINE is removed by a healthcare provider certified to perform insertions.
Please see additional Important Safety Information in the Package Insert that can be found at probuphine.com or by following this link http://probuphinerems.com/wp-content/uploads/2016/02/final-approved-pi.pdf.
Coltrin & Associates, Inc.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/probuphine-wins-popular-sciences-best-of-whats-new-award-300352584.html
SOURCE Braeburn Pharmaceuticals